Abcam, ab257774, Human TYMP (Thymidine Phosphorylase) knockout HeLa cell lysate

Size: 1Kit
TYMP KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TYMP, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Thymidine phosphorylase also known as platelet-derived endothelial cell growth factor (PD-ECGF) acts mechanically to catalyze the reversible phosphorolysis of thymidine into thymine and 2-deoxy-alpha-D-ribose-1-phosphate. With a mass of approximately 44 kDa this enzyme is present in various tissues including blood vessels and macrophages. Its expression tends to be higher in tumor tissues which suggests a specific role in cancer biology.
Biological function summary
The enzyme participates in pyrimidine nucleoside metabolism providing an alternate route for thymidine catabolism. It is not part of a larger complex functioning independently to promote angiogenesis. Thymidine phosphorylase enhances the degradation of extracellular thymidine which can positively impact nucleotide balance within cells aiding DNA synthesis and repair.
Pathways
Thymidine phosphorylase operates significantly within the nucleotide salvage pathways. It is essential for clarifying thymidine availability for DNA synthesis. The enzyme links with enzymes like dihydropyrimidine dehydrogenase in pyrimidine degradation playing a critical role in maintaining cellular nucleotide homeostasis.
Altered activity of thymidine phosphorylase correlates with cancer and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). In tumors increased levels of this enzyme facilitate angiogenesis contributing to tumor growth and metastasis. In MNGIE mutations in this enzyme lead to imbalances in nucleotides causing mitochondrial dysfunction. The enzyme's dysregulation connects to angiogenesis-related proteins like VEGF in cancer highlighting potential therapeutic targets.